This company listing is no longer active
Bionano Genomics Past Earnings Performance
Past criteria checks 0/6
Bionano Genomics's earnings have been declining at an average annual rate of -43.5%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 26% per year.
Key information
-43.5%
Earnings growth rate
59.7%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 26.0% |
| Return on equity | -68.2% |
| Net Margin | -465.0% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bionano Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 32 | -147 | 97 | 55 |
| 31 Mar 23 | 30 | -140 | 92 | 52 |
| 31 Dec 22 | 28 | -133 | 86 | 49 |
| 30 Sep 22 | 26 | -117 | 81 | 44 |
| 30 Jun 22 | 23 | -106 | 76 | 38 |
| 31 Mar 22 | 21 | -92 | 68 | 30 |
| 31 Dec 21 | 18 | -72 | 57 | 22 |
| 30 Sep 21 | 16 | -61 | 47 | 16 |
| 30 Jun 21 | 13 | -51 | 40 | 12 |
| 31 Mar 21 | 11 | -41 | 32 | 10 |
| 31 Dec 20 | 9 | -41 | 30 | 10 |
| 30 Sep 20 | 7 | -37 | 28 | 10 |
| 30 Jun 20 | 8 | -33 | 23 | 10 |
| 31 Mar 20 | 9 | -32 | 23 | 10 |
| 31 Dec 19 | 10 | -30 | 20 | 9 |
| 30 Sep 19 | 11 | -28 | 18 | 10 |
| 30 Jun 19 | 11 | -27 | 17 | 10 |
| 31 Mar 19 | 12 | -23 | 16 | 9 |
| 31 Dec 18 | 12 | -18 | 14 | 9 |
| 30 Sep 18 | 11 | -18 | 13 | 9 |
| 30 Jun 18 | 11 | -18 | 13 | 10 |
| 31 Mar 18 | 10 | -22 | 14 | 11 |
| 31 Dec 17 | 10 | -23 | 14 | 12 |
| 31 Dec 16 | 7 | -19 | 13 | 11 |
Quality Earnings: 2Y30 is currently unprofitable.
Growing Profit Margin: 2Y30 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2Y30 is unprofitable, and losses have increased over the past 5 years at a rate of 43.5% per year.
Accelerating Growth: Unable to compare 2Y30's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2Y30 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.2%).
Return on Equity
High ROE: 2Y30 has a negative Return on Equity (-68.23%), as it is currently unprofitable.